Novartis temporarily suspended the production of the company’s Lutathera and Pluvicto cancer therapies at facilities in Italy and New Jersey after potential quality issues were discovered in their manufacturing.
Novartis’ proposed drug for adults diagnosed with a certain type of advanced prostate cancer was given the green light for commercialization.
Targeted radioligand therapy 177Lu-PSMA-617 from Novartis significantly improved overall survival (OS) and radiographic progression-free survival (rPFS) in patients with PSMA-positive metastatic castration-resistant prostate cancer, according to findings from the Phase III VISION trial.
The return on R&D investment for leading biopharmaceutical manufacturers fell to a nine-year low while the U.S. FDA approved a record-breaking amount of novel medicines during 2018.
Swiss pharma giant Novartis announced plans to seek regulatory approval for 60 new treatments between 2019 and 2021.